This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Arthritis Therapeutics Market To 2018 - Novel Oral JAK Inhibitors And Biologic Disease Modifying Anti-Rheumatic Drugs (DMARD) Will Drive Continued Growth Across Key Indications

Table 28: Ankylosing Spondylitis Therapeutics Market, Global, Revenue ($m), 2004-2010 56

Table 29: Ankylosing Spondylitis Therapeutics Market, Global, Revenue Forecasts ($m), 2010-2018 56

Table 30: Ankylosing Spondylitis Therapeutics Market, Global, Annual Cost of Treatment ($), 2004-2010 57

Table 31: Ankylosing Spondylitis Therapeutics Market, Global, Annual Cost of Treatment ($), 2010-2018 57

Table 32: Ankylosing Spondylitis Therapeutics Market, Global, Treatment Usage Patterns (millions), 2004-2010 58

Table 33: Ankylosing Spondylitis Therapeutics Market, Global, Treatment Usage Patterns (millions), 2010-2018 59

Table 34: Ankylosing Spondylitis Therapeutics-Marketed Products, 2010 60

Table 35: Arthritis Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2004-2010 63

Table 36: Arthritis Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2010-2018 63

Table 37: Arthritis Therapeutics Market, The US, Revenue ($bn), 2004-2010 64

Table 38: Arthritis Therapeutics Market, The US, Revenue Forecasts ($bn), 2010-2018 64

Table 39: Arthritis Therapeutics Market, The US Market, Annual Cost of Treatment ($), 2004-2010 65

Table 40: Arthritis Therapeutics Market, The US Market, Annual Cost of Treatment ($), 2010-2018 65

Table 41: Arthritis Therapeutics Market, The US, Treatment Usage Patterns (millions), 2004-2010 66

Table 42: Arthritis Therapeutics Market, The US, Treatment Usage Patterns (millions), 2010-2018 66

Table 43: Arthritis Therapeutics Market, Top Five EU Countries, Revenue ($bn), 2004-2010 68

Table 44: Arthritis Therapeutics Market, Top Five EU Countries, Revenue Forecasts ($bn), 2010-2018 68

Table 45: Arthritis Therapeutics Market, Top Five EU Countries, Annual Cost of Treatment ($), 2004-2010 69

Table 46: Arthritis Therapeutics Market, Top Five EU Countries, Annual Cost of Treatment ($), 2010-2018 69

Table 47: Arthritis Therapeutics Market, Top Five EU Countries, Treatment Usage Patterns (millions), 2004-2010 70

Table 48: Arthritis Therapeutics Market, Top Five EU Countries, Treatment Usage Patterns (millions), 2010-2018 71

Table 49: Arthritis Therapeutics Market, Japan, Revenue ($bn), 2004-2010 72

Table 50: Arthritis Therapeutics Market, Japan, Revenue Forecast ($bn), 2010-2018 72

Table 51: Arthritis Therapeutics Market, Japan, Annual Cost of Treatment ($), 2004-2010 73

Table 52: Arthritis Therapeutics Market, Japan, Annual Cost of Treatment ($), 2010-2018 73

Table 53: Arthritis Therapeutics Market, Japan, Treatment Usage Patterns (millions), 2004-2010 74

Table 54: Arthritis Therapeutics Market, Japan, Treatment Usage Patterns (millions), 2010-2018 74

Table 55: Arthritis Therapeutics Market, Osteoarthritis Therapeutics Pipeline, Development Stage Molecules, 2011 79

4 of 7

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,336.93 -79.92 -0.46%
S&P 500 2,013.64 -7.61 -0.38%
NASDAQ 4,686.5750 +3.1680 0.07%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs